QLM2022

QLM2022 is a long-acting, extended-release microsphere formulation of leuprorelin acetate, a synthetic nonapeptide and potent gonadotropin-releasing hormone (GnRH) receptor agonist. Developed by Nuoqiao Pharmaceuticals (Chengdu) Co., Ltd., it is specifically designed for the treatment of advanced hormone-sensitive prostate cancer and prostate adenocarcinoma. The drug's mechanism involves an initial stimulation of the GnRH receptors in the pituitary gland, causing a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Continuous exposure to the sustained-release formulation subsequently leads to the downregulation and desensitization of these receptors, resulting in a profound suppression of gonadotropin secretion and a reduction of serum testosterone to castrate levels. This chemical castration effectively inhibits the growth of testosterone-dependent prostate cancer cells. QLM2022 is typically administered as a 3-month depot injection, utilizing a ready-to-use microsphere technology to improve ease of administration and patient compliance.

Other names

Leuprorelin acetate microspheresLeuprorelin acetate sustained-release microspheres醋酸亮丙瑞林缓释微球